The Technical Analyst
Abcam plc [ABCM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Abcam plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.04% GBP23.99
America/New_York / 5 des 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5 521.32 mill |
| EPS: | 0.0100 |
| P/E: | 2 399.00 |
| Earnings Date: | Aug 31, 2023 |
| SharesOutstanding: | 230.15 mill |
| Avg Daily Volume: | 5.82 mill |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | n/a | n/a | ||||
| Asset | n/a | |||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 2 399.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 408.11x |
| Company: PE 2 399.00 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
GBP 23.82 - 24.16 ( +/- 0.69%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | GBP23.99 (0.04% ) |
| Volume | 7.43 mill |
| Avg. Vol. | 5.82 mill |
| % of Avg. Vol | 127.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ABCM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ABCM
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Latest Press Releases
2023-12-06 07:30:00 - Press Release
Danaher Completes Acquisition Of Abcam
Washington , dec. 6, 2023 /prnewswire/ -- danaher corporation (nyse:dhr) ("danaher") announced today it has completed its acquisition of abcam plc (nasdaq:abcm) ("abcam"). the acquisition of abcam for $24.00 per share in cash was implemented by way of a court-sanctioned scheme of arrangement under the uk companies act 2006 (the "scheme") and the scheme became effective in accordance with its terms on december 6, 2023.
2023-12-04 16:01:00 - Press Release
Acquisition Of Abcam By Danaher Approved By The High Court Of Justice Of England And Wales
Cambridge, england & waltham, mass.--(business wire)--abcam plc (nasdaq: abcm) (‘abcam', the ‘group' or the ‘company'), a global leader in the supply of life science research tools, entered into a definitive agreement on august 26, 2023 relating to its proposed acquisition by danaher corporation (nyse: dhr) (‘danaher') for $24.00 per share in cash (the ‘transaction'), to be implemented by way of a court-sanctioned scheme of arrangement under part 26 of the companies act 2006 (the ‘scheme‘). the.
2023-11-01 07:00:00 - Press Release
Statement From Dr. Jonathan Milner On The Suspension Of The “vote Against” Campaign
Statement from dr. jonathan milner on the suspension of the “vote against” campaign cambridge, england, 1 november 2023 - jonathan milner, the founder and one of the largest investors in abcam plc (“abcam” or the “company”) (nyse: abcm) with ownership of 6.16% of the company, today issued the following statement in relation to the proposed acquisition of abcam by danaher corporation (nyse: dhr) or its affiliates (“danaher”). “after extensive feedback from the majority of abcam's shareholders, i have today decided to suspend my “vote against” campaign.
2023-10-23 02:00:00 - Press Release
Jonathan Milner Issues Statement Responding To The Glass Lewis Report
Jonathan milner issues statement responding to the glass lewis report welcomes the glass lewis report's observations on the disproportionate rewards for abcam's executive directors and on the identified issues with peer group valuation strategies urges shareholders to continue to vote against the current proposed acquisition of abcam by danaher cambridge, england, 23 october 2023 – jonathan milner, the founder and one of the largest investors in abcam plc (“abcam” or the “company”) (nyse: abcm) with ownership of 6.16% of the company, has today issued the following statement in response to a 21 october 2023 report from glass lewis. jonathan milner urges shareholders to continue to vote against the current proposed acquisition of abcam by danaher corporation (nyse: dhr) or its affiliates (“danaher”).
2023-10-16 13:12:00 - Press Release
Jonathan Milner Issues Statement Responding To Iss Report
Jonathan milner issues statement responding to iss report urges shareholders to disregard the iss report and continue to vote against the current proposed acquisition of abcam by danaher cambridge, england, 16 october 2023 – jonathan milner, the founder and one of the largest shareholders in abcam plc (“abcam” or the “company”) (nyse: abcm) with ownership of 6.16% of the company, has today issued the following statement in response to a 16 october 2023 report from institutional shareholder service (“iss”). jonathan milner urges shareholders to continue to vote against the current proposed acquisition of abcam by danaher corporation (nyse: dhr) or its affiliates (“danaher”).
Latest News
2023-12-06 08:14:21 - Reuters
Danaher completes $5.7 billion acquisition of Abcam
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.
2023-10-16 08:46:56 - Proactive Investors
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short
In an exclusive interview with Thomas Warner (TW) of Proactive London, Dr Jonathan Milner (JM), the founder of life sciences company Abcam PLC (NASDAQ:ABCM), discusses why he believes the $24 per share acquisition offer from Danaher (NYSE:DHR) severely undervalues the company. Milner criticises the timing of the deal and advises shareholders to consider whether the $5.7 billion acquisition is in their best interest.
2023-10-05 12:47:10 - Zacks Investment Research
GMED or ABCM: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Abcam PLC Sponsored ADR (ABCM). But which of these two stocks offers value investors a better bang for their buck right now?
2023-08-28 16:55:38 - Investopedia
Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings
Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.
2023-08-28 09:32:52 - Proactive Investors
Danaher acquires biotech supplier Abcam for $5.7B
Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who were also bidding for the company including Agilent Technologies (NYSE:A), according to media reports.
2023-08-28 08:33:36 - Reuters
Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln
Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services.
2023-08-28 08:32:00 - Barrons
Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium.
The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each.
2023-08-28 07:54:00 - Market Watch
Abcam agrees to be acquired by Danaher in $5.7B deal
Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday.
2023-08-25 14:04:10 - Reuters
Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources
Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday.
2023-06-23 15:44:06 - The Motley Fool
Why Shares of Abcam Are Jumping Friday
Abcam specializes in products, such as assays or reagents, used in biologic drug discovery. The company saw revenue grow but reported a loss in 2022.